A naturally occurring rev1-vpu fusion gene does not confer a fitness advantage to HIV-1

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Langer, Simon M ^a   Hopfensperger, Kristina ^a   Iyer, Shilpa S ^b   Kreider, Edward F ^b   Learn, Gerald H ^b   Lee, Lan Hui ^a,c   Hahn, Beatrice H ^b   Sauter, Daniel ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD4 ANTIGEN; CELL SURFACE PROTEIN; DNA POLYMERASE REV1; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NTB A PROTEIN; REV1 VPU FUSION PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIRUS RNA; VPU PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; REV PROTEIN; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENVELOPE GENE; FRAMESHIFT MUTATION; FUSION GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LYMPHOID TISSUE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROVIRUS; REGULATOR GENE; REV1 VPU FUSION GENE; RNA SPLICING; VIRUS GENE; VIRUS REPLICATION; GENE EXPRESSION REGULATION; GENE FUSION; GENETICS;

GENE EXPRESSION REGULATION, VIRAL; GENE FUSION; HEK293 CELLS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84953338806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142118     Document Type: Article

References (37)

1. Ocwieja KE, Sherrill-Mix S, Mukherjee R, Custers-Allen R, David P, Brown M, et al. Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. Nucleic Acids Res. 2012; 40: 10345-10355. doi: 10.1093/nar/gks753
2. Salfeld J, Göttlinger HG, Sia RA, Park RE, Sodroski JG, Haseltine WA. A tripartite HIV-1 tat-env-rev fusion protein. EMBO J. 1990; 9: 965-970.
3. Benko DM, Schwartz S, Pavlakis GN, Felber BK. A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins. J Virol. 1990; 64: 2505-2518.
4. Cohen EA, Lu Y, Göttlinger H, Dehni G, Jalinoos Y, Sodroski JG, et al. The T open reading frame of human immunodeficiency virus type 1. J Acquir Immune Defic Syndr. 1990; 3: 601-608.
5. Göttlinger HG, Dorfman T, Cohen EA, Haseltine WA. The role of the tnv protein and tnv RNA splicing signals in replication of HIV-1 IIIB isolates. Virology. 1992; 189: 618-628.
6. Furtado MR, Balachandran R, Gupta P, Wolinsky SM. Analysis of alternatively spliced human immunodeficiency virus type-1 mRNA species, one of which encodes a novel tat-env fusion protein. Virology. 1991; 185: 258-270.
7. Kraus MH, Parrish NF, Shaw KS, Decker JM, Keele BF, Salazar-Gonzalez JF, et al. A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from revvpu-env cassettes and reduces virion infectivity in pseudotyping assays. Virology. 2010; 397: 346-357. doi: 10.1016/j.virol.2009.11.019
8. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol. 1992; 66: 7193-7200.
9. Neil SJD, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451: 425-430. doi: 10.1038/nature06553
10. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008; 3: 245-252. doi: 10.1016/j.chom.2008.03.001
11. Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, et al. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe. 2010; 8: 397-409. doi: 10.1016/j.chom.2010.10.008
12. Moll M, Andersson SK, Smed-Sörensen A, Sandberg JK. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood. 2010; 116: 1876-1884. doi: 10.1182/blood-2009-09-243667
13. Akari H, Bour S, Kao S, Adachi A, Strebel K. The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors. J Exp Med. 2001; 194: 1299-1311.
14. Bour S, Perrin C, Akari H, Strebel K. The human immunodeficiency virus type 1 Vpu protein inhibits NFkappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem. 2001; 276: 15920-15928. doi: 10.1074/jbc.M010533200
15. Leulier F, Marchal C, Miletich I, Limbourg-Bouchon B, Benarous R, Lemaitre B. Directed expression of the HIV-1 accessory protein Vpu in Drosophila fat-body cells inhibits Toll-dependent immune responses. EMBO Rep. 2003; 4: 976-981. doi: 10.1038/sj.embor.embor936
16. Sauter D, Hotter D, Van Driessche B, Störzel CM, Kluge SF, Wildum S, et al. Differential Regulation of NF-κB-Mediated Proviral and Antiviral Host Gene Expression by Primate Lentiviral Nef and Vpu Proteins. Cell Rep. 2015; 10: 586-599. doi: 10.1016/j.celrep.2014.12.047
17. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-Activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature. 1989; 338: 254-257. doi: 10.1038/338254a0
18. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J Virol. 2008; 82: 3952-3970. doi: 10.1128/JVI.02660-07
19. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A. 2013; 110: 6626-6633. doi: 10.1073/pnas.1304288110
20. Tanaka M, Herr W. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell. 1990; 60: 375-386.
21. Wu Y, Beddall MH, Marsh JW. Rev-dependent lentiviral expression vector. Retrovirology. 2007; 4: 12. doi: 10.1186/1742-4690-4-12
22. Glushakova S, Baibakov B, Margolis LB, Zimmerberg J. Infection of human tonsil histocultures: A model for HIV pathogenesis. Nat Med. 1995; 1: 1320-1322. doi: 10.1038/nm1295-1320
23. Krummheuer J, Johnson AT, Hauber I, Kammler S, Anderson JL, Hauber J, et al. A minimal uORF within the HIV-1 vpu leader allows efficient translation initiation at the downstream env AUG. Virology. 2007; 363: 261-271. doi: 10.1016/j.virol.2007.01.022
24. Anderson JL, Johnson AT, Howard JL, Purcell DFJ. Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs. J Virol. 2007; 81: 4664-4676. doi: 10.1128/JVI.01028-06
25. Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS Lond Engl. 2011; 25: 679-689. doi: 10.1097/QAD.0b013e328342ff93
26. Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, et al. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog. 2015; 11: e1004565. doi: 10.1371/journal.ppat.1004565
27. Liu MKP, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest. 2013; 123: 380-393. doi: 10. 1172/JCI65330
28. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol. 1993; 67: 6365-6378.
29. Schwartz S, Felber BK, Fenyö EM, Pavlakis GN. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol. 1990; 64: 5448-5456.
30. Schwartz S, Felber BK, Pavlakis GN. Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol Cell Biol. 1992; 12: 207-219.
31. Guerrero S, Batisse J, Libre C, Bernacchi S, Marquet R, Paillart J-C. HIV-1 Replication and the Cellular Eukaryotic Translation Apparatus. Viruses. 2015; 7: 199-218. doi: 10.3390/v7010199
32. Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH. HIV-1 infection of non-dividing cells: evidence that the amino-Terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 1997; 16: 4531-4539. doi: 10.1093/emboj/16.15.4531
33. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et al. Production of acquired immunodeficiency syndrome-Associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59: 284-291.
34. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol. 1987; 7: 379-387.
35. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998; 72: 2855-2864.
36. Shugars DC, Smith MS, Glueck DH, Nantermet PV, Seillier-Moiseiwitsch F, Swanstrom R. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol. 1993; 67: 4639-4650.
37. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003; 31: 3406-3415. doi: 10.1093/nar/gkg595